Skip to NavigationSkip to content

Epicast: Brain Cancer – Epidemiology Forecast to 2024

Published on 07/04/17 at 09:17am
IMAGE CREDIT: Lee Health, Vimeo

Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumours, (ABTA, 2014). The type and severity of a brain tumour is defined by the cells from which the tumour originated, as well as by the proliferative potential of the abnormal growth. Only malignant tumours are designated as cancer (NCI, 2015). Primary brain tumours are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumours are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age (in 10- year age groups). Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumours originating in the CNS (ICD-10 codes C70– C72).

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%.

Below mentioned figures (7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014 and 2024 and 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014 and 2024) present the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer in the 7MM in 2014 and 2024, respectively.

 

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches